Construction And Expression Of A Noval Immunotoxin Against Hepatocellular Carcinoma And Its Activity Detection

Human hepatocellular carcinoma(HCC) is one of the most common cancers worldwide and remains one of leading causes of death from cancer in China. With the development of medical imaging technology, the diagnosis has been more precise ,but the application of molecular biological technology in the treatment of HCC is very little. The conventional approaches include surgery, chemotherapy, and radiotherapy take up the first status in cancer cure。 but most of human cancers remains incurable and prognosis remains poor. It is clear that new therapeutic approaches are urgently needed for those patients who have unresectable cancer at the time of diagnosis.Differentiation antigens, hormones, growth factor receptors, and viral antigens are expressed on the surface of a variety of malignant and dysfunctional cells in humans, which is the base of targeted therapy. Targeted therapy has become a major part of biotherapy of cancer after the conventional therapeusis. Over the past years, monoclonal antibodies have attracted enormous interest as targeted therapeutics, especially advances in immunoconjugate technology have revitalized the "magic bullet" concept of immunotherapeutics for the treatment of cancer. More importantly, antibody fusion proteins such as immunotoxins which were derived by coupling toxins to scFv antibody fragments using recombinant DNA technology have greatly increased the potential for cancer therapeutic oppottunities. Immunotoxin is composed of "bullet" and vector. "Bullet" is creature toxin, derived from plant and bacteria, which is catalyzed by enzymes. Once recombinant immunotoxins bind to receptors on cancer cells, the toxin enters and kills the cells. Pseudomonas exotoxin A enzymatically ADP-ribosylates elongation factor 2, restrain protein synthesis. Presently, some achievements of immunotoxins have been made in breast cancer,...